Gotowa bibliografia na temat „Surrogate endpoints”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Surrogate endpoints”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Surrogate endpoints"
Banerjee, Buddhananda, i Atanu Biswas. "True endpoint reduction by surrogate endpoints". Communications in Statistics - Simulation and Computation 46, nr 8 (27.05.2016): 6645–53. http://dx.doi.org/10.1080/03610918.2016.1171350.
Pełny tekst źródłaCiani, Oriana, Bogdan Grigore, Hedwig Blommestein, Saskia de Groot, Meilin Möllenkamp, Stefan Rabbe, Rita Daubner-Bendes i Rod S. Taylor. "Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies". Medical Decision Making 41, nr 4 (10.03.2021): 439–52. http://dx.doi.org/10.1177/0272989x21994553.
Pełny tekst źródłaCiani, Oriana, Sarah Davis, Paul Tappenden, Ruth Garside, Ken Stein, Anna Cantrell, Everardo D. Saad, Marc Buyse i Rod S. Taylor. "VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS". International Journal of Technology Assessment in Health Care 30, nr 3 (lipiec 2014): 312–24. http://dx.doi.org/10.1017/s0266462314000300.
Pełny tekst źródłaEllenberg, SS. "Surrogate endpoints". British Journal of Cancer 68, nr 3 (wrzesień 1993): 457–59. http://dx.doi.org/10.1038/bjc.1993.369.
Pełny tekst źródłaHughes, Michael D. "Evaluating surrogate endpoints". Controlled Clinical Trials 23, nr 6 (grudzień 2002): 703–7. http://dx.doi.org/10.1016/s0197-2456(02)00264-7.
Pełny tekst źródłaHahn, Andreas, Andreas Podbielski, Markus M. Heimesaat, Hagen Frickmann i Philipp Warnke. "Binary surrogate endpoints in clinical trials from the perspective of case definitions". European Journal of Microbiology and Immunology 11, nr 1 (30.03.2021): 18–22. http://dx.doi.org/10.1556/1886.2020.00031.
Pełny tekst źródłaKuller, Lewis H. "Clinical trials: surrogate endpoints or hard endpoints?" American Journal of Cardiology 88, nr 2 (lipiec 2001): 59–61. http://dx.doi.org/10.1016/s0002-9149(01)01786-6.
Pełny tekst źródła&NA;. "Biomarkers and Surrogate Endpoints". American Journal of Therapeutics 6, nr 4 (lipiec 1999): 179–80. http://dx.doi.org/10.1097/00045391-199907000-00001.
Pełny tekst źródłaSomberg, J. "Biomarker and Surrogate Endpoints". American Journal of Therapeutics 10, nr 4 (lipiec 2003): 239–40. http://dx.doi.org/10.1097/00045391-200307000-00001.
Pełny tekst źródłaFurgerson, James L., William N. Hannah i Jennifer C. Thompson. "Challenge of Surrogate Endpoints". Southern Medical Journal 105, nr 3 (marzec 2012): 156–60. http://dx.doi.org/10.1097/smj.0b013e318249891e.
Pełny tekst źródłaRozprawy doktorskie na temat "Surrogate endpoints"
Feng, Chunyao Seaman John Weldon. "Bayesian evaluation of surrogate endpoints". Waco, Tex. : Baylor University, 2006. http://hdl.handle.net/2104/4187.
Pełny tekst źródłaNordman, Ina IC Clinical School St Vincent's Hospital Faculty of Medicine UNSW. "Surrogate endpoints of survival in metastatic carcinoma". Publisher:University of New South Wales. Clinical School - St Vincent's Hospital, 2008. http://handle.unsw.edu.au/1959.4/42791.
Pełny tekst źródłaWang, Hui. "Response Adaptive Randomization using Surrogate and Primary Endpoints". VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4517.
Pełny tekst źródłaBark, Charles. "CLINICAL SYMPTOMS AND MICROBIOLOGICAL OUTCOMES IN TUBERCULOSIS TREATMENT TRIALS". Case Western Reserve University School of Graduate Studies / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=case1307630776.
Pełny tekst źródłaDimier, Natalie. "Statistical methodology for evaluation of time-to-event surrogate and true endpoints in small-sample meta-analysis of clinical trials". Thesis, University of Reading, 2017. http://centaur.reading.ac.uk/78463/.
Pełny tekst źródłaSavina, Marion. "Critères de Substitution à la Survie Globale dans les Essais Cliniques Randomisés en Cancérologie". Thesis, Bordeaux, 2017. http://www.theses.fr/2017BORD0894/document.
Pełny tekst źródłaIn cancer randomized controlled trials (RCT), a surrogate endpoint is intended to substitute a clinically relevant endpoint, e.g. overall survival (OS), and it is supposed to predict treatment effect. Alternative endpoints, for example progression-free survival, are increasingly being used in place of OS as primary efficacy endpoints in RCTs. In practice however, the surrogate properties of these endpoints are not systematically assessed. We performed a systematic literature review to identify surrogate endpoints validated in oncology. We next conducted MAs to evaluate surrogate endpoints in two cancer settings: advanced soft-tissue sarcoma and adjuvant breast cancer. Results could not definitely validate surrogate endpoints in these indications. OS must remain the primary efficacy endpoint in these settings, even though alternative endpoints may provide valuable input in earlier phase studies (phase II trials, futility analyses). This work provides key information for the design of cancer RCTs, in particular for the choice of primary endpoints to assess treatment efficacy
Branchoux, Sébastien. "Critères de substitution de la survie globale chez les patients atteints de cancer métastatique traités par inhibiteurs de points de contrôle immunologiques". Thesis, Bordeaux, 2020. http://www.theses.fr/2020BORD0253.
Pełny tekst źródłaAdvanced cancer treatment has been recently revolutionized by the development of the immune-checkpoint inhibitors (ICI). These immunomodulatory monoclonal antibodies are designed to either elicit a novel anti-tumoral immune response or revitalize an existing one to fight against cancer. Patients with cancer are living longer due to these improved therapies. Powering a study for overall survival (OS), the gold standard primary endpoint in randomized controlled trial (RCT) of anticancer drugs is becoming increasingly challenging. Therefore, it is of importance to identify and validate novel surrogate endpoints (SE) for OS in ICI-treated patients for expediting patients’ access to innovative and potentially life extending medicines. We first systematically reviewed published studies reporting on an association between alternative endpoints and OS in ICI-treated patients. Then, based on the learnings from this systematic literature review and from the specificity of the mechanism of action of ICIs, we evaluated the surrogacy properties of an emerging intermediate endpoint in solid tumors, namely time to next treatment (TNT), in ICI-treated patients with advanced melanoma and renal cell carcinoma (aRCC), through recent innovative statistical models for the validation of SE. Based on the results of these surrogacy analyses, TNT seems a promising SE for OS in RCTs of ICI-treated patients with advanced melanoma and aRCC. We encourage sponsors of RCTs of ICI to carefully collect the date of subsequent systemic treatment, so that surrogacy analyses could consequently be performed with a larger number of RCTs in order to confirm our findings
Sofeu, Casimir. "Développement de méthodes pour la validation de critères de substitution en survie : méta-analyses de cancer". Thesis, Bordeaux, 2019. http://www.theses.fr/2019BORD0383.
Pełny tekst źródłaSurrogate endpoint can be used instead of the most relevant clinical endpointto assess the efficiency of a new treatment. In a meta-analysis framework, the classical approach for the validation of surrogate endpoint is based on a two-step analysis. For failure time endpoints, this approach often raises estimation issues.We propose a one-step validation approach based on a joint frailty and a joint frailty-copula model.The models include both trial-level and individual-level random effects or copula functions. We chose a non-parametric form of the baseline hazard functions using splines. We estimated parameters and hazard functions using a semi-parametric penalized marginal likelihood method, considering various numerical integration methods. Both individual level and trial level surrogacy were evaluated using Kendall's tau and coefficient of determination. The performance of the estimators was evaluated using simulation studies. The models were applied to individual patient data meta-analyses in cancer clinical trials for assesing potentiel surrogate endpoint to overall survival.The models were quite robust with a reduction of convergence and model estimation issues encountered in the two-step approach.We developed a user friendly R package implementing the models
Qin, Lang. "Magnetic resonance imaging lesion count as a surrogate endpoint in relapsing-remitting multiple sclerosis clinical trials". Thesis, University of British Columbia, 2011. http://hdl.handle.net/2429/37092.
Pełny tekst źródłaMunoz, Daniel. "The Effects of Fruit and Vegetable Extracts on Surrogate Endpoint Biomarkers in Curatively Treated Head and Neck Squamous Cell Carcinoma Patients". Scholarly Repository, 2009. http://scholarlyrepository.miami.edu/oa_theses/186.
Pełny tekst źródłaKsiążki na temat "Surrogate endpoints"
Burzykowski, Tomasz, Geert Molenberghs i Marc Buyse, red. The Evaluation of Surrogate Endpoints. New York, NY: Springer New York, 2005. http://dx.doi.org/10.1007/b138566.
Pełny tekst źródłaMedicine), Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of. Surrogate endpoints in evaluating the effectiveness of drugs against HIV infection and AIDS: September 11-12, 1989 : conference summary. Washington, D.C: National Academy Press, 1990.
Znajdź pełny tekst źródłaMorganroth, Joel, i E. Neil Moore, red. Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-1505-6.
Pełny tekst źródłaAlonso, Ariel. Applied Surrogate Endpoint Evaluation Methods with SAS and R. Boca Raton : CRC Press, 2017.: Chapman and Hall/CRC, 2016. http://dx.doi.org/10.1201/9781315372662.
Pełny tekst źródłaInstitute of Medicine (U.S.). Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, Institute of Medicine (U.S.). Board on Health Care Services, Institute of Medicine (U.S.). Board on Health Sciences Policy, Institute of Medicine (U.S.). Food and Nutrition Board i National Academies Press (U.S.), red. Perspectives on biomarker and surrogate endpoint evaluation: Discussion forum summary. Washington, D.C: National Academies Press, 2011.
Znajdź pełny tekst źródłaSymposium on New Drugs and Devices (10th 1989 Philadelphia, Pa.). Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia: Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31-November 1, 1989. Boston: Kluwer Academic Publishers, 1990.
Znajdź pełny tekst źródłaKim, Sang-gyŏm. Saenghwahakchŏk pʻyojija mit taeri kyŏlgwa pyŏnsu ŭi PK/PD modelling chŏgyong e kwanhan yŏnʼgu =: The study for evaluation of PK/PD modeling using biomarker and surrogate endpoint. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.
Znajdź pełny tekst źródłaThe Evaluation Of Surrogate Endpoints. Springer, 2010.
Znajdź pełny tekst źródłaMolenberghs, Geert, Marc Buyse i Tomasz Burzykowski. The Evaluation of Surrogate Endpoints. Springer, 2009.
Znajdź pełny tekst źródłaWagner, J. A. Surrogate Endpoints in Medicine (Disease Markers). Ios Pr Inc, 2002.
Znajdź pełny tekst źródłaCzęści książek na temat "Surrogate endpoints"
Ekhtiari, Seper, Ryan P. Coughlin, Nicole Simunovic i Olufemi R. Ayeni. "Surrogate Endpoints". W Evidence-Based Surgery, 85–92. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-05120-4_9.
Pełny tekst źródłaFleming, Thomas R., Victor DeGruttola i David L. Demets. "Surrogate Endpoints". W Methods and Applications of Statistics in Clinical Trials, 878–86. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118596005.ch74.
Pełny tekst źródłaCleophas, Ton J., i Aeilko H. Zwinderman. "Validating Surrogate Endpoints". W Machine Learning in Medicine, 53–64. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-6886-4_7.
Pełny tekst źródłaMolenberghs, Geert, Ziv Shkedy, Burzykowski Tomasz, Marc Buyse, Ariel Alonso Abad i Wim Van der Elst. "Evaluation of Surrogate Endpoints". W Handbook of Statistical Methods for Randomized Controlled Trials, 567–600. Boca Raton: Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781315119694-26.
Pełny tekst źródłaCiccone, Giovannino, i Ileana Baldi. "Surrogate Endpoints of Clinical Benefit". W Imaging Tumor Response to Therapy, 3–14. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2613-1_1.
Pełny tekst źródłaShkedy, Ziv, i Franz Torres Barbosa. "Bayesian Evaluation of Surrogate Endpoints". W Statistics for Biology and Health, 253–70. New York, NY: Springer New York, 2005. http://dx.doi.org/10.1007/0-387-27080-9_15.
Pełny tekst źródłaPaoletti, Xavier, Federico Rotolo i Stefan Michiels. "Assessing the Value of Surrogate Endpoints". W Textbook of Clinical Trials in Oncology, 425–46. Boca Raton, Florida : CRC Press, [2019]: Chapman and Hall/CRC, 2019. http://dx.doi.org/10.1201/9781315112084-20.
Pełny tekst źródłaGeorge, Stephen L. "Surrogate Endpoints in Cancer Clinical Trials". W Statistical Models in Epidemiology, the Environment, and Clinical Trials, 251–72. New York, NY: Springer New York, 2000. http://dx.doi.org/10.1007/978-1-4612-1284-3_8.
Pełny tekst źródłaCleophas, Ton J., i Aeilko H. Zwinderman. "Validating Surrogate Endpoints of Clinical Trials". W Statistics Applied to Clinical Studies, 569–78. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-2863-9_52.
Pełny tekst źródłaPassiglia, Francesco, Giuseppe Cicero, Marta Castiglia i Viviana Bazan. "Biomarkers as Prognostic, Predictive, and Surrogate Endpoints". W Current Clinical Pathology, 31–41. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2047-1_4.
Pełny tekst źródłaStreszczenia konferencji na temat "Surrogate endpoints"
Coxson, Harvey O., Michael L. Watkins, Nicholas W. Locantore, Peter M. Calverley, Bartolome Celli i Victor M. Pinto-Plata. "Computed Tomography And Associations To Lung Mechanics The Evaluation Of COPD Longitudinally To Identify Predictive Surrogate Endpoints (ECLIPSE) Study". W American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5136.
Pełny tekst źródłaCoxson, HO, HA Gietema, PS Bakke, SS Sharma i LD Edwards. "Contributions of Airway Wall Thickening and Emphysema to Airflow Limitation: ”Evaluation of COPD Longitudinally To Identify Predictive Surrogate Endpoints” (ECLIPSE) Study." W American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a6200.
Pełny tekst źródłaAnzueto, A., JA Wedzicha, JR Hurst, J. Vestbo, J. Yates, R. Tal-Singer i DP Miller. "Diagnosis of COPD Exacerbations and Their Distribution Based on GOLD Severity Stages. Data from the Evaluation of COPD Longitudinally To Identify Predictive Surrogate Endpoints (ECLIPSE) Study." W American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a1527.
Pełny tekst źródłaCoxson, Harvey O., Lisa Edwards, Per Bakke, Edwin K. Silverman, William MacNee i &. ECLIPSE Investigators. "Relationship Between Lung Volumes And The Extent Of Emphysema As Assessed By Computed Tomography In The "Evaluation Of COPD Longitudinally To Identify Predictive Surrogate Endpoints" (ECLIPSE) Study". W American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5781.
Pełny tekst źródłaMaselli, Diego J., Hana Müllerova, Nicholas W. Locantore, Jorgen Vestbo, John R. Hurst, Jadwiga A. Wedzicha i Antonio Anzueto. "Risk Factors And Mortality Associated With Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Exacerbations During The 3-Year Follow-Up In The Evaluation Of COPD Longitudinally To Identify Predictive Surrogate Endpoints (Eclipse) Cohort". W American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5374.
Pełny tekst źródłaFuhlbrigge, A. L., T. W. Harrison, M. Fagerås, A. Jauhiainen, L. E. J. M. Scheepers, J. Zangrilli i C. A. Da Silva. "An Investigation of Geographic Influence on CompEx, a Surrogate Endpoint for Severe Asthma Exacerbations". W American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1298.
Pełny tekst źródłaHeckman-Stoddard, B., RA Lubet, AM Bode i CJ Grubbs. "P3-11-07: Mammary Gland Biopsy To Examine Surrogate Endpoint Biomarkers of Preventive Agent Efficacy." W Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p3-11-07.
Pełny tekst źródłaGabler, Nicole B., Benjamin French, Brian L. Strom, Harold I. Palevsky, Darren Taichman, Steven M. Kawut i Scott D. Halpern. "Validation Of Six-Minute-Walk Distance As A Surrogate Endpoint In Pulmonary Arterial Hypertension Trials". W American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4092.
Pełny tekst źródłaHarris, Wayne B., Dana C. Nickleach, Yuan Liu, Omer Kucuk i Viraj A. Master. "Abstract C15: Inflammation-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma". W Abstracts: Sixth AACR Conference: The Science of Cancer Health Disparities; December 6–9, 2013; Atlanta, GA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7755.disp13-c15.
Pełny tekst źródłaStamp, L., M. Morillon, W. Taylor, N. Dalbeth, J. Singh i R. Christensen. "OP0267 Serum urate as a surrogate endpoint for gout flares: results of a systematic review and meta-regression analysis of randomized trials". W Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1544.
Pełny tekst źródła